Bicycle Therapeutics PLC
NASDAQ:BCYC
Bicycle Therapeutics PLC?
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
We'll email you a reminder when the closing price reaches USD.
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
13.31
27.51
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
What unique competitive advantages
does Bicycle Therapeutics PLC hold over its rivals?
What risks and challenges
does Bicycle Therapeutics PLC face in the near future?
Is it considered overvalued or undervalued
based on the latest financial data?
Provide an overview of the primary business activities
of Bicycle Therapeutics PLC.
Provide an overview of the primary business activities
of Bicycle Therapeutics PLC.
What unique competitive advantages
does Bicycle Therapeutics PLC hold over its rivals?
What risks and challenges
does Bicycle Therapeutics PLC face in the near future?
Has there been any significant insider trading activity
in Bicycle Therapeutics PLC recently?
Is it considered overvalued or undervalued
based on the latest financial data?
Show all valuation multiples
for Bicycle Therapeutics PLC.
Provide P/S
for Bicycle Therapeutics PLC.
Provide P/E
for Bicycle Therapeutics PLC.
Provide P/OCF
for Bicycle Therapeutics PLC.
Provide P/FCFE
for Bicycle Therapeutics PLC.
Provide P/B
for Bicycle Therapeutics PLC.
Provide EV/S
for Bicycle Therapeutics PLC.
Provide EV/GP
for Bicycle Therapeutics PLC.
Provide EV/EBITDA
for Bicycle Therapeutics PLC.
Provide EV/EBIT
for Bicycle Therapeutics PLC.
Provide EV/OCF
for Bicycle Therapeutics PLC.
Provide EV/FCFF
for Bicycle Therapeutics PLC.
Provide EV/IC
for Bicycle Therapeutics PLC.
Show me price targets
for Bicycle Therapeutics PLC made by professional analysts.
What are the Revenue projections
for Bicycle Therapeutics PLC?
How accurate were the past Revenue estimates
for Bicycle Therapeutics PLC?
What are the Net Income projections
for Bicycle Therapeutics PLC?
How accurate were the past Net Income estimates
for Bicycle Therapeutics PLC?
What are the EPS projections
for Bicycle Therapeutics PLC?
How accurate were the past EPS estimates
for Bicycle Therapeutics PLC?
What are the EBIT projections
for Bicycle Therapeutics PLC?
How accurate were the past EBIT estimates
for Bicycle Therapeutics PLC?
Compare the revenue forecasts
for Bicycle Therapeutics PLC with those of its competitors based on recent analyst estimates.
Compare the intrinsic valuations
of Bicycle Therapeutics PLC and its key competitors using the latest financial data.
Compare historical revenue growth rates
of Bicycle Therapeutics PLC against its competitors.
Analyze the profit margins
(gross, operating, and net) of Bicycle Therapeutics PLC compared to its peers.
Compare the P/E ratios
of Bicycle Therapeutics PLC against its peers.
Discuss the investment returns and shareholder value creation
comparing Bicycle Therapeutics PLC with its peers.
Analyze the financial leverage
of Bicycle Therapeutics PLC compared to its main competitors.
Show all profitability ratios
for Bicycle Therapeutics PLC.
Provide ROE
for Bicycle Therapeutics PLC.
Provide ROA
for Bicycle Therapeutics PLC.
Provide ROIC
for Bicycle Therapeutics PLC.
Provide ROCE
for Bicycle Therapeutics PLC.
Provide Gross Margin
for Bicycle Therapeutics PLC.
Provide Operating Margin
for Bicycle Therapeutics PLC.
Provide Net Margin
for Bicycle Therapeutics PLC.
Provide FCF Margin
for Bicycle Therapeutics PLC.
Show all solvency ratios
for Bicycle Therapeutics PLC.
Provide D/E Ratio
for Bicycle Therapeutics PLC.
Provide D/A Ratio
for Bicycle Therapeutics PLC.
Provide Interest Coverage Ratio
for Bicycle Therapeutics PLC.
Provide Altman Z-Score Ratio
for Bicycle Therapeutics PLC.
Provide Quick Ratio
for Bicycle Therapeutics PLC.
Provide Current Ratio
for Bicycle Therapeutics PLC.
Provide Cash Ratio
for Bicycle Therapeutics PLC.
What is the historical Revenue growth
over the last 5 years for Bicycle Therapeutics PLC?
What is the historical Net Income growth
over the last 5 years for Bicycle Therapeutics PLC?
What is the current Free Cash Flow
of Bicycle Therapeutics PLC?
Discuss the annual earnings per share (EPS)
trend over the past five years for Bicycle Therapeutics PLC.
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
UK |
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
918.6m USD | -0.1 | ||
FR |
Pharnext SCA
OTC:PNEXF
|
6T USD | -221 001.2 |
|
|
US |
Abbvie Inc
NYSE:ABBV
|
309.5B USD | 23.4 |
|
|
US |
Amgen Inc
NASDAQ:AMGN
|
141.7B USD | 30.4 |
|
|
US |
Gilead Sciences Inc
NASDAQ:GILD
|
111.2B USD | 9.8 |
|
|
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
104B USD | 22.5 |
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -491.9 |
|
AU |
CSL Ltd
ASX:CSL
|
135.3B AUD | 24.4 |
|
|
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
75.8B USD | 16.4 |
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -52.1 |
|
NL |
argenx SE
XBRU:ARGX
|
38.5B EUR | -108.2 |
|
EBIT Growth | EV/EBIT to Growth | |||||
---|---|---|---|---|---|---|
UK |
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Average EV/EBIT:
21.1
|
N/A | N/A | ||
FR |
Pharnext SCA
OTC:PNEXF
|
Negative Multiple: -221 001.2 | N/A | N/A |
|
|
US |
Abbvie Inc
NYSE:ABBV
|
23.4
|
24%
|
1 |
|
|
US |
Amgen Inc
NASDAQ:AMGN
|
30.4
|
24%
|
1.3 |
|
|
US |
Gilead Sciences Inc
NASDAQ:GILD
|
9.8
|
10%
|
1 |
|
|
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
22.5
|
13%
|
1.7 |
|
|
US |
E
|
Epizyme Inc
F:EPE
|
Negative Multiple: -491.9 | N/A | N/A |
|
AU |
CSL Ltd
ASX:CSL
|
24.4
|
16%
|
1.5 |
|
|
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
16.4
|
12%
|
1.4 |
|
|
US |
S
|
Seagen Inc
F:SGT
|
Negative Multiple: -52.1 | N/A | N/A |
|
NL |
argenx SE
XBRU:ARGX
|
Negative Multiple: -108.2 | N/A | N/A |
|
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.